Symposium – iCAN – Digital Precision Cancer Medicine

Welcome to our exciting symposium on precision cancer medicine in Helsinki!

Registration is closed and all seats are filled.

The Symposium is streamed and the link is https://enchant.fi/icanfci/symposium2022

For more information, please contact ican-fci@helsinki.fi

VENUE: Hilton Helsinki Kalastajatorppa
Conference and Events Center, Kalastajatorpantie 1, Helsinki, tel: +358-945811

Thursday, September 22, 2022 - Siirtomaasali 1

8:00 – Breakfast & Registration

9:00 Opening words. Satu Mustjoki, iCAN Scientific Director, University of Helsinki & HUS Helsinki University Hospital

9:05 Awarding of the Eero Saksela prize by Vesa Kataja, Chair of the Scientific Advisory Board of the Finnish Cancer Institute

9:15 Special lecture: Kari Alitalo, University of Helsinki: A proxy of stemness and progression in intestinal cancer

10:00 Keynote: Peter Kraft, Harvard University: Polygenic risk scores and tailored cancer screening

10:45 Coffee, posters, and exhibition

SESSION 1. Chairs: Johanna Arola & Martti Färkkilä

11:15 Christian Meisel, Hedera Dx: Actionable ctDNA based insights for precision cancer medicine

11:45 Jesús Bañales, Biodonostia: Genetic background of primary sclerosing cholangitis associated cholangiocarcinoma (PSC-CCA)

12:15 Cyriel Ponsioen, Amsterdam AMC: Primary sclerosing cholangitis (PSC) dysplasia surveillance

12:45 Short presentation selected from abstracts: Nelli Sjöblom, HUS Helsinki University Hospital: Next generation sequencing of brush samples may improve detection of biliary neoplasia in PSC patients

13:00 – 14:00 Lunch, posters, and exhibition

SESSION 2. Chairs: Caroline Heckman & Markus Vähä-Koskela

14:00 Daniel Peeper, Netherlands Cancer Institute: Rational concepts for tumor & immune cell therapy combinations

14:30 Karin de Visser, Netherlands Cancer Institute: Innate-adaptive immune cell crosstalk dictates response to immune checkpoint blockade in breast cancer

15:00 René Medema, Netherlands Cancer Institute: Chromatin-dependent control of the DNA damage response

15:30 Eero Saksela prize winner presentation

15:45 Group Photo, coffee

SESSION 3. Chairs: Tomi Mäkelä & Johanna Ivaska

16:15 Johanna Ivaska, University of Turku: Targeting KRAS-mutant cancers by disrupting KRAS-SHANK3 interaction

16:45 Francesca M. Buffa, University of Oxford: Machine Learning and Systems Biology approaches in Precision Oncology

17:15 Pekka Katajisto, University of Helsinki: Stem cells and tumorigenesis – a fight between self-renewing cells

17:45 Eero Saksela prize winner presentation

18:00 Adjournement

19:00- Dinner at Kalastajatorppa, Pyöreä Sali

Friday, September 23, 2022 - Siirtomaasali 1

7:45 Breakfast & Registration

SESSION 4. Chairs: Tomi Mäkelä & Minna Anttonen

8:30 Special lecture: Bettina Ryll, Melanoma Patient Network Europe: From good to great: What patients can do for your research?

9:00 Panel discussion on patient involvement.

Moderators: Sara Lassfolk and Marketta Liljeström, iCAN Patient and Citizen Advisory Board.

Panel members: Sampsa Hautaniemi, University of Helsinki, Jarmo Wahlfors, Cancer Foundations Finland, Aino Kormilainen, HUS

9:30 Coffee, posters, and exhibition

SESSION 5. Chairs: Ilkka Ilonen & Tiina Vesterinen

10:00 Keynote: Pasi Jänne, Dana-Farber Cancer Institute, Harvard Medical School: Beyond the magic bullet

10:45 Prasad Adusumilli, Memorial Sloan Kettering Cancer Center: CAR-T cell therapy for solid tumors; new opportunities and challenges

11:15 Lynette Sholl, Brigham and Women’s Hospital/Harvard Medical School: Molecular diagnostics of cancer to support individualized therapy: perspectives from a clinical lab

11:45 Åslaug Helland, Oslo University Hospital: Personalized medicine in thoracic oncology; where are we now and where we are going – where we have the most to gain?

12:15 – 13:30 Lunch, posters, and exhibition

SESSION 6. Chairs: Sirpa Leppä & Päivi Ojala

13:30 Marco Gerlinger, Barts Cancer Institute and St Bartholomew’s Hospital, London: Gastrointestinal cancer evolution: mechanisms and implications for precision therapy

14:00 Kjetil Taskén, Institute of Cancer Research, Oslo University Hospital: A national precision cancer medicine implementation initiative for Norway

14:30 Short presentation selected from abstracts, Sakari Vanharanta, University of Helsinki: Lineage factor-dependent oncogenic signaling in kidney cancer

14:45 Coffee, posters, and exhibition

SESSION 7. Chairs: Päivi Ojala & Sirpa Leppä

15:15 Keynote: Michel Sadelain, Memorial Sloan Kettering Cancer Center: CAR T cells and the Living Drug Concept

16:00 Dario Campana, NUS Yong Loo Lin School of Medicine: Disrupting the treatment of lymphoid malignancies with CAR-T cells

16:30 Maria Themeli, Amsterdam UMC: Designing optimal dual-targeting of CAR T cells: the BETTER gate

17:00 Satu Mustjoki, University of Helsinki: Mechanisms of natural killer cell immune evasion by functional immune profiling

17:30 Closing words, Johanna Arola, the Chair of the Organizing Committee

17:45 Adjournement

Organising committee:

Johanna Arola, chair

Tomi Mäkelä, vice chair

Caroline Heckman

Päivi Ojala

Sirpa Leppä

Ilkka Ilonen

Secretariat:

Tiina Vesterinen, FCI

Leena Karhinen, iCAN

Marketta Liljeström, iCAN PCAB

Satu Sankkila, iCAN

Saija Piiroinen, iCAN

Contact: ican-fci@helsinki.fi